After seeing its clinical program stall following the failure of a Phase IIb trial testing NTx-265 in acute stroke, Stem Cell Therapeutics Corp. is reinventing itself. (See BioWorld Today, May 26, 2010.) Read More
The field of hepatitis C virus (HCV) research is hot. So hot, in fact, that in January the BioWorld Today staff ranked the unfolding story of the exceptional performance of HCV potential treatments from the clinic in second place in the top 10 most impactful stories of last year. (See BioWorld Today, Jan. 2, 2013.) Read More
